CR11684A - Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa - Google Patents

Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa

Info

Publication number
CR11684A
CR11684A CR11684A CR11684A CR11684A CR 11684 A CR11684 A CR 11684A CR 11684 A CR11684 A CR 11684A CR 11684 A CR11684 A CR 11684A CR 11684 A CR11684 A CR 11684A
Authority
CR
Costa Rica
Prior art keywords
dihydropirazolones
propil
hif
replaced
hydroxylase inhibitors
Prior art date
Application number
CR11684A
Other languages
English (en)
Inventor
Mario Jeske
Ingo Flamme
Friederike Stoll
Hartmut Beck
Metin Akbaba
Original Assignee
Argent Marine Man Inc
Argent Marine Man O Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40673347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR11684(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Argent Marine Man Inc, Argent Marine Man O Inc filed Critical Argent Marine Man Inc
Publication of CR11684A publication Critical patent/CR11684A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

La presente solicitud se refiere a nuevos derivados de dihidropirazolona sustituidos, a procesos para su preparación, a su uso para el tratamiento y/o la prevención de enfermedades y a su uso para la preparación de medicamentos para el tratamiento y/o la prevención de enfermedades
CR11684A 2008-04-23 2010-09-21 Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa CR11684A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102008020113A DE102008020113A1 (de) 2008-04-23 2008-04-23 Substituierte Dihydropyrazolone und ihre Verwendung

Publications (1)

Publication Number Publication Date
CR11684A true CR11684A (es) 2011-03-24

Family

ID=40673347

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11684A CR11684A (es) 2008-04-23 2010-09-21 Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa

Country Status (29)

Country Link
US (3) US8067407B2 (es)
EP (1) EP2265602B1 (es)
JP (1) JP5579165B2 (es)
KR (1) KR20100135838A (es)
CN (1) CN102015685B (es)
AR (1) AR071376A1 (es)
AU (1) AU2009240311B2 (es)
BR (1) BRPI0911594A2 (es)
CA (1) CA2722016C (es)
CL (1) CL2009000906A1 (es)
CO (1) CO6300844A2 (es)
CR (1) CR11684A (es)
DE (1) DE102008020113A1 (es)
DO (1) DOP2010000282A (es)
EC (1) ECSP10010494A (es)
ES (1) ES2535458T3 (es)
HN (1) HN2010001920A (es)
IL (1) IL208136A0 (es)
MA (1) MA32251B1 (es)
MX (1) MX2010010324A (es)
NZ (1) NZ588721A (es)
PE (1) PE20091732A1 (es)
RU (1) RU2509080C9 (es)
SV (1) SV2010003674A (es)
TW (1) TWI433846B (es)
UA (1) UA105487C2 (es)
UY (1) UY31765A (es)
WO (1) WO2009129945A1 (es)
ZA (1) ZA201006719B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008020113A1 (de) * 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituierte Dihydropyrazolone und ihre Verwendung
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
DE102006050516A1 (de) * 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
CN103052632B (zh) * 2010-08-18 2014-03-19 山东亨利医药科技有限责任公司 二氢吡唑类化合物
DE102010044131A1 (de) 2010-11-18 2012-05-24 Bayer Schering Pharma Aktiengesellschaft Substituiertes Natrium-1H-pyrazol-5-olat
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
WO2012126275A1 (zh) * 2011-03-18 2012-09-27 山东亨利医药科技有限责任公司 含有螺环的二氢吡唑类化合物
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
CA2851082A1 (en) * 2011-10-06 2013-04-11 Merck Sharp & Dohme Corp. 1,3-substituted azetidine pde10 inhibitors
CN104144925A (zh) * 2011-10-17 2014-11-12 拜耳知识产权有限责任公司 作为hif抑制剂的取代的噁二唑基吡啶酮和噁二唑基哒嗪酮
EP3608317A1 (en) 2012-01-12 2020-02-12 Yale University Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase
ES2699404T3 (es) * 2012-03-30 2019-02-11 Daiichi Sankyo Co Ltd Derivado de 4-alcanoilamino-3-pirazolona
RS56255B1 (sr) * 2012-05-08 2017-11-30 Bayern Pharma Ag Postupak proizvodnje jedinjenja triazola
JOP20190080A1 (ar) 2016-10-14 2019-04-11 Bayer Pharma AG مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها
ES2946551T3 (es) * 2017-10-17 2023-07-20 Palau Pharma S L U Síntesis de compuestos de 4-aminopirimidina
CN109694380B (zh) * 2017-10-23 2022-09-27 中国医药研究开发中心有限公司 二氢吡唑啉酮类化合物及其制备方法和医药用途
CN111825690B (zh) * 2019-04-17 2022-09-27 中国医药研究开发中心有限公司 一种phd抑制剂的新晶型及其制备方法
CN111825689B (zh) * 2019-04-17 2023-05-05 中国医药研究开发中心有限公司 一种二氢吡唑啉酮类化合物的晶型及其制备方法
CA3160364A1 (en) * 2019-11-19 2021-05-27 Modag Gmbh Compounds, and their use for the diagnosis, treatment and prevention of diseases associated with the aggregation of alpha-synuclein

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4075003A (en) 1975-12-11 1978-02-21 Eli Lilly And Company Novel herbicidal method utilizing 1,4-diphenyl-3-pyrazolin-5-ones
GR63123B (en) 1975-12-11 1979-09-11 Lilly Co Eli Preparation process of novel 1,4-diphenyl-3-pyrazolin-5-ones
PL103509B1 (pl) 1976-09-20 1979-06-30 Lilly Co Eli Srodek chwastobojczy
US4663327A (en) 1984-05-23 1987-05-05 Bayer Aktiengesellschaft 1-heteroaryl-4-aryl-pyrazolin-5-ones
DE3443308A1 (de) 1984-11-28 1986-05-28 Bayer Ag, 5090 Leverkusen 1-heteroaryl-4-aryl-pyrazolin-5-one zur verwendung als arzneimittel
DE3527157A1 (de) 1985-07-30 1987-02-12 Bayer Ag 1-heteroaryl-4-aryl-pyrazol-derivate
FR2725988B1 (fr) 1994-10-24 1997-01-24 Roussel Uclaf Nouveaux derives de pyrazolones et pyrazoles acides, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
DE19909237A1 (de) 1999-03-03 2000-09-07 Merck Patent Gmbh Pyrazol-3-on-derivate
US6878729B2 (en) 2001-05-04 2005-04-12 The Procter & Gamble Company Medicinal uses of dihydropyrazoles
US6884804B2 (en) 2001-05-16 2005-04-26 Vertex Pharmaceuticals Incorporated Inhibitors of Src and other protein kinases
EP1458383B1 (en) 2001-12-18 2007-11-21 Merck & Co., Inc. Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
WO2003074550A2 (en) 2002-03-01 2003-09-12 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
CA2522441A1 (en) * 2003-03-27 2004-10-14 Emory University Hif-1 inhibitors
US20060194807A1 (en) 2003-04-03 2006-08-31 Cosford Nicholas D P Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
CA2525298A1 (en) 2003-05-01 2004-11-18 Panacea Pharmaceuticals, Inc. Methods of treating ischemic related conditions
EP1646382A4 (en) 2003-06-30 2010-07-21 Hif Bio Inc COMPOUNDS, COMPOSITIONS AND METHODS
CN1842332A (zh) * 2003-06-30 2006-10-04 Hif生物公司 化合物、组合物及方法
CA2614068A1 (en) 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
DE102008020113A1 (de) * 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituierte Dihydropyrazolone und ihre Verwendung
RU2401258C2 (ru) 2005-03-16 2010-10-10 Авентис Фармасьютикалз Инк. Дипиразолы в качестве средств для центральной нервной системы
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
DE102006050515A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung
DE102006050513A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substitiuierte Dihydropyrazolone und ihre Verwendung
DE102006050516A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
JP5237712B2 (ja) * 2008-07-25 2013-07-17 公立大学法人 滋賀県立大学 静電紡糸装置

Also Published As

Publication number Publication date
US20140038938A1 (en) 2014-02-06
DE102008020113A1 (de) 2009-10-29
EP2265602B1 (de) 2015-04-08
AU2009240311A1 (en) 2009-10-29
UA105487C2 (uk) 2014-05-26
AU2009240311B2 (en) 2014-02-27
SV2010003674A (es) 2011-01-14
US8580778B2 (en) 2013-11-12
MX2010010324A (es) 2010-11-05
JP2011518794A (ja) 2011-06-30
HN2010001920A (es) 2013-10-22
WO2009129945A1 (de) 2009-10-29
KR20100135838A (ko) 2010-12-27
EP2265602A1 (de) 2010-12-29
IL208136A0 (en) 2010-12-30
JP5579165B2 (ja) 2014-08-27
CA2722016C (en) 2016-09-20
CL2009000906A1 (es) 2010-04-09
HK1156306A1 (en) 2012-06-08
ZA201006719B (en) 2011-11-30
RU2509080C9 (ru) 2014-08-20
NZ588721A (en) 2012-10-26
MA32251B1 (fr) 2011-04-01
PE20091732A1 (es) 2009-12-05
UY31765A (es) 2009-12-14
CN102015685A (zh) 2011-04-13
BRPI0911594A2 (pt) 2017-10-10
ES2535458T3 (es) 2015-05-11
CO6300844A2 (es) 2011-07-21
US20120035151A1 (en) 2012-02-09
US8067407B2 (en) 2011-11-29
RU2010147404A (ru) 2012-05-27
TWI433846B (zh) 2014-04-11
DOP2010000282A (es) 2010-11-15
RU2509080C2 (ru) 2014-03-10
US20090269420A1 (en) 2009-10-29
ECSP10010494A (es) 2010-10-30
CN102015685B (zh) 2014-10-15
AR071376A1 (es) 2010-06-16
CA2722016A1 (en) 2009-10-29
TW201006825A (en) 2010-02-16

Similar Documents

Publication Publication Date Title
CR11684A (es) Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa
UY31228A1 (es) Ariloxazoles sustituidos y su uso
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
ECSP088904A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
CO6771409A2 (es) Acidos 1-bencilcicloalquilcarboxilicos sustituidos y su uso
CR20140392A (es) Dihidropirazolonas sustituidas
SV2009003299A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
DOP2011000285A (es) 2-acetamido-5-aril-1, 2, 4-triazolonas sustituidas y su uso
ECSP077296A (es) Fenilaminotiazoles sustituidos y su uso
UY31922A (es) Compuestos
CR20110318A (es) Compuestos, composición farmacéutica y métodos para utilizarse en el tratamiento de trastornos metabólicos
DOP2007000043A (es) Derivados de cromanol sustituidos y su uso
AR058098A1 (es) Derivados de acidos dicarboxilicos y su uso
PA8846201A1 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales
NI201500115A (es) Estra-1,3,5(10), 16-tetraeno-3-carboxamidas para la inhibición de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
CR11869A (es) 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
CU20100260A7 (es) 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
CU20100183A7 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa
DOP2005000174A (es) Fenilaminotiazoles sustituidos y su uso
CR10449A (es) Arilimidazolonas y ariltriazolonas sustituidas como inihibidores de receptores de vasopresina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)